Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-1 15% in Alpha1-Antitrypsin Deficiency
NCT04722887Phase 2Completed
- Sponsor
- Grifols
- Start
- Dec 2021
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Started Dec 2021; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04722887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722887.